Arexvy, launched in the United States recently, recorded third quarter sales of 709 million pounds ($862 million), trouncing analysts' expectations of 358 million pounds, according to a company-compiled consensus.
GSK accounts for close to two-thirds of RSV shots given in the United States since early September, according to IQVIA data.
Full-year sales are seen between 900 million pounds and 1 billion pounds for the shot, GSK said.
The company faces about 79,000 cases related to Zantac in the United States, with 73,000 of them in Delaware and scheduled for trial starting January 2024.
For the third quarter, Shingrix, the company's top-selling drug for shingles, generated 825 million pounds in sales.
Persons:
Dado Ruvic, Abrysvo, Dani Saurymper, Emma Walmsley, Eva Mathews, Maggie Fick, Tomasz Janowski, Mark Potter
Organizations:
GSK, GlaxoSmithKline, REUTERS, stg, CVS, Pfizer, Pacific Asset Management, GSK's, Thomson
Locations:
London, United States, U.S, Europe, Japan, Delaware, Bengaluru